Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.155
+0.025 (0.80%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Voyager Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Voyager Therapeutics stock have an average target of 14.86, with a low estimate of 7.00 and a high estimate of 30. The average target predicts an increase of 371.00% from the current stock price of 3.16.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Voyager Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 4 | 3 |
| Buy | 3 | 3 | 3 | 3 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +850.87% | Apr 8, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 → $12 | Strong Buy | Maintains | $14 → $12 | +280.35% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +850.87% | Mar 13, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $12 → $10 | Buy | Maintains | $12 → $10 | +216.96% | Mar 12, 2025 |
| Wedbush | Wedbush | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Mar 12, 2025 |
Financial Forecast
Revenue This Year
67.47M
from 80.00M
Decreased by -15.67%
Revenue Next Year
68.84M
from 67.47M
Increased by 2.04%
EPS This Year
-1.71
from -1.13
EPS Next Year
-1.67
from -1.71
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 154.0M | 154.3M | 129.0M | ||
| Avg | 67.5M | 68.8M | 83.3M | ||
| Low | 3.9M | 19.6M | 19.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 92.5% | 128.7% | 87.3% | ||
| Avg | -15.7% | 2.0% | 20.9% | ||
| Low | -95.1% | -70.9% | -71.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.64 | -0.65 | -0.98 | ||
| Avg | -1.71 | -1.67 | -1.54 | ||
| Low | -2.55 | -2.54 | -2.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.